以极后区综合征为表现的视神经脊髓炎谱系疾病1例
A Case of Neuromyelitis Optica Spectrum Disorder Presenting as Area Postrema Syndrome
摘要: 目的:探讨视神经脊髓炎谱系疾病(Neuromyelitis Optica Spectrum Disorder, NMOSD)的主要临床表现、早期诊断和治疗方法,提高临床医师对NMOSD的认知水平。方法:回顾分析我院1例以极后区综合征(Area Postrema Syndrome, APS)为表现的视神经脊髓炎谱系疾病患者相关病例资料、辅助检查结果及诊疗过程并复习相关文献。结果:患者因“反复呕吐1月余,加重5天”于2023年9月收住于我院,早期使用抑酸护胃等药物治疗后效果欠佳,随后出现视物模糊、右侧肢体乏力等神经系统症状,根据患者临床表现、实验室检查和其他辅助检查结果,最终确诊为NMOSD中的APS,经积极治疗后患者好转出院。结论:NMOSD是一种较为罕见的疾病,临床医师应提高对它的认知,尽可能减少漏诊、误诊,提高NMOSD的早期诊出率。
Abstract: Objective: To explore the main clinical manifestations, early diagnosis, and treatment strategies of Neuromyelitis Optica Spectrum Disorder (NMOSD), aiming to enhance clinicians’ understanding of the disease. Methods: A retrospective analysis was conducted on the case data, auxiliary examination results, and treatment process of a patient diagnosed with NMOSD presenting as Area Postrema Syndrome (APS) admitted to our hospital. Relevant literature was also reviewed. Results: The patient was admitted to our hospital in September, 2023, due to “recurrent vomiting for over a month, worsening for 5 days”. Initial treatment with acid suppression and gastric protection was ineffective. Subsequently, the patient developed neurological symptoms, including blurred vision and right-sided limb weakness. Based on the clinical manifestations, laboratory tests, and auxiliary examination results, the patient was ultimately diagnosed with APS, a subtype of NMOSD. Following active treatment, the patient’s condition improved. Conclusion: NMOSD is a relatively rare disease. Clinicians should increase their awareness of the condition to minimize misdiagnosis and missed diagnosis, thereby improving the early diagnosis rate of NMOSD.
文章引用:黄健, 王迪, 唐运思, 官语, 刘序友. 以极后区综合征为表现的视神经脊髓炎谱系疾病1例[J]. 临床医学进展, 2025, 15(8): 1113-1119. https://doi.org/10.12677/acm.2025.1582341

参考文献

[1] 黄德晖, 吴卫平, 胡学强. 中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版) [J]. 中国神经免疫学和神经病学杂志, 2021, 28(6): 423-436.
[2] Wingerchuk, D.M. and Lucchinetti, C.F. (2022) Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 387, 631-639. [Google Scholar] [CrossRef] [PubMed]
[3] Papp, V., Magyari, M., Aktas, O., Berger, T., Broadley, S.A., Cabre, P., et al. (2021) Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology, 96, 59-77. [Google Scholar] [CrossRef] [PubMed]
[4] Wingerchuk, D.M., Pittock, S.J., Lucchinetti, C.F., Lennon, V.A. and Weinshenker, B.G. (2007) A Secondary Progressive Clinical Course Is Uncommon in Neuromyelitis Optica. Neurology, 68, 603-605. [Google Scholar] [CrossRef] [PubMed]
[5] Hor, J.Y., Asgari, N., Nakashima, I., Broadley, S.A., Leite, M.I., Kissani, N., et al. (2020) Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology, 11, Article No. 501. [Google Scholar] [CrossRef] [PubMed]
[6] Fujihara, K. (2019) Neuromyelitis Optica Spectrum Disorders: Still Evolving and Broadening. Current Opinion in Neurology, 32, 385-394. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, C., Shi, M., Zhu, M., Chu, F., Jin, T. and Zhu, J. (2022) Comparisons of Clinical Phenotype, Radiological and Laboratory Features, and Therapy of Neuromyelitis Optica Spectrum Disorder by Regions: Update and Challenges. Autoimmunity Reviews, 21, Article ID: 102921. [Google Scholar] [CrossRef] [PubMed]
[8] Holroyd, K.B., Manzano, G.S. and Levy, M. (2020) Update on Neuromyelitis Optica Spectrum Disorder. Current Opinion in Ophthalmology, 31, 462-468. [Google Scholar] [CrossRef] [PubMed]
[9] Wingerchuk, D.M., Banwell, B., Bennett, J.L., Cabre, P., Carroll, W., Chitnis, T., et al. (2015) International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology, 85, 177-189. [Google Scholar] [CrossRef] [PubMed]
[10] Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., Pittock, S.J. and Weinshenker, B.G. (2007) The Spectrum of Neuromyelitis Optica. The Lancet Neurology, 6, 805-815. [Google Scholar] [CrossRef] [PubMed]
[11] Jarius, S. and Wildemann, B. (2013) The History of Neuromyelitis Optica. Journal of Neuroinflammation, 10, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[12] 邹彤, 黄靖, 卢洁. 视神经脊髓炎谱系疾病磁共振研究现状及进展[J]. 医学影像学杂志, 2023, 33(7): 1244-1247.
[13] Camara-Lemarroy, C.R. and Burton, J.M. (2018) Area Postrema Syndrome: A Short History of a Pearl in Demyelinating Diseases. Multiple Sclerosis Journal, 25, 325-329. [Google Scholar] [CrossRef] [PubMed]
[14] Kleiter, I. and Gold, R. (2016) Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics, 13, 70-83. [Google Scholar] [CrossRef] [PubMed]
[15] Bonnan, M., Valentino, R., Debeugny, S., Merle, H., Fergé, J., Mehdaoui, H., et al. (2017) Short Delay to Initiate Plasma Exchange Is the Strongest Predictor of Outcome in Severe Attacks of NMO Spectrum Disorders. Journal of Neurology, Neurosurgery & Psychiatry, 89, 346-351. [Google Scholar] [CrossRef] [PubMed]
[16] Pittock, S.J., Zekeridou, A. and Weinshenker, B.G. (2021) Hope for Patients with Neuromyelitis Optica Spectrum Disorders—From Mechanisms to Trials. Nature Reviews Neurology, 17, 759-773. [Google Scholar] [CrossRef] [PubMed]
[17] Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., et al. (2020) Safety and Efficacy of Rituximab in Neuromyelitis Optica Spectrum Disorders (RIN-1 Study): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Neurology, 19, 298-306. [Google Scholar] [CrossRef] [PubMed]
[18] Levy, M. (2020) Interleukin-6 Receptor Blockade for the Treatment of NMOSD. The Lancet Neurology, 19, 370-371. [Google Scholar] [CrossRef] [PubMed]
[19] Kümpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Häußler, V., et al. (2023) Update on the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD)—Revised Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack Therapy and Long-Term Management. Journal of Neurology, 271, 141-176. [Google Scholar] [CrossRef] [PubMed]
[20] Bichuetti, D.B., Perin, M.M.d.M., Souza, N.A.d. and Oliveira, E.M.L.d. (2018) Treating Neuromyelitis Optica with Azathioprine: 20-Year Clinical Practice. Multiple Sclerosis Journal, 25, 1150-1161. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, Y., Zhao, C., Pan, Z., Zhang, R., Li, Y., Li, H., et al. (2025) Long-Term Efficacy and Safety of Low-Dose Rituximab Strategy in Neuromyelitis Optica Spectrum Disorder: A Retrospective Cohort Study on Treatment Compliance and Clinical Outcomes. Orphanet Journal of Rare Diseases, 20, Article No. 244. [Google Scholar] [CrossRef] [PubMed]